The change in Ig regulation from children to adults disconnects the correlation with the 3’RR hs1.2 polymorphism
© Serone et al.; licensee BioMed Central Ltd. 2014
Received: 7 January 2014
Accepted: 25 September 2014
Published: 13 November 2014
In the immune system, the serum levels of immunoglobulin (Ig) increase gradually during ageing. Through B cell development, the Ig heavy chain expression is modulated by a regulatory region at the 3’ of the constant alpha gene (3’RR), in single copy in rodents and, due to a large duplication, in two copies in apes. The human 3’RR1 and 3’RR2 are both characterized by three enhancers, the central of which, namely hs1.2, is highly polymorphic. Human hs1.2 has four different variants with unique binding sites for transcription factors (e.g. NF-kB and SP1) and shows variable allelic frequencies in populations with immune disorders. In previous works, we have reported that in several autoimmune diseases the *2 allele of hs1.2 is genetically associated to high level of IgM in peripheral blood. In subjects with altered levels of circulating Ig, an increased level was associated to *2 allele of hs1.2 and low levels corresponded to high frequency of *1 allele.
During ageing there is a physiological increase of Ig concentrations in the serum. Therefore, for this study, we hypothesized that the hs1.2 variants may impact differently the levels of secreted Ig during the growth.
We have correlated the allelic frequencies of hs1.2 with IgM, IgG and IgA serum concentrations in two cohorts of healthy people of different age and after three years follow-up in children homozygous for the allele. Here we show that when the expression levels of Ig in children are low and medium, the frequencies of *1 and *2 alleles are the same. Instead, when the Ig expression levels are high, there is a significantly higher frequency of the allele *2. The follow-up of children homozygous for *1 and *2 alleles showed that the increase or decrease of circulating Ig was not dependent on the number of circulating mature B cells.
These data support the idea that under physiologic condition there is a switch of regulative pathways involved in the maturation of Ig during ageing. This mechanism is evidenced by hs1.2 variants that in children but not in adults participate to Ig production, coordinating the three class levels.
The serum levels of Immunoglobulins (Ig) are the result of regulated processes involving B cell development and the progressive expression of immunoglobulin heavy chain (Igh) genes . During B cell differentiation, IgH locus (14q32.33) undergoes various DNA rearrangements and epigenetic changes, necessary for the generation of antibody repertoire -.
The human IgH locus is characterized by two 3’ regulatory regions (3’RR) caused by a duplication, both downstream with respect to heavy chain alpha (Cα) genes (see Figure1). Each 3’RR is composed of three different enhancers. In both cases the central enhancer hs1.2 is located in one region with a palindromic sequence conserved in structure but not in sequence - and contains a 40-bp tandem-repeat DNA motif, polymorphic for number of copies and conserved in different species of mammals ,. In humans this 40 bp region is repeated from one to four times. The hs1.2 allele with two copies of 40 bp element is called allele *2 and carries a unique binding site for NF-κB transcription factor . In the machinery of the Ig maturation the class switches when IgG2, IgG4, IgA2 and IgE are produced. Since 3’RR1 is deleted along with the rest of the heavy chain involved in the excision, the switched allele will be under the control of the 3’RR2. Of note, more then 95% of human subjects bear *4 allele of hs1.2 in 3’RR2 giving a high homogeneity of the expression and not the variability observed for 3’RR1 (see Figure1). Different selective advantages or disadvantages are related to possible different functions. Hs1.2 allele *2 in the distal 3’RR1 is significantly more frequent in patients with several autoimmune diseases, such as celiac disease, psoriasis, systemic sclerosis, rheumatoid arthritis, and lupus erythematosus with respect to healthy control group -, and is associated with high levels of IgM in peripheral blood . Of note, patients with IgA deficiency show a significant correlation with hs1.2 allele *1 . Finally, new evidence have been reported on the differences among hs1.2 polymorphic variants indicating complex interactions between binding factors and enhancers after stimulation of mouse and human B cells .
It has already been described that follow-up of children through adulthood shows a gradual increase of Ig concentrations in serum . Therefore, in order to determine if there is a genetic correlation between hs1.2 alleles and the levels of circulating Ig in children and adults, we compared the concentration of circulating Ig in association with allelic frequency of hs1.2 enhancer in one cohort of adults and one of young healthy subjects. Our data show that the IgM, IgG and IgA serum concentrations are significantly associated with the hs1.2 alleles in youth, but not in adult population, suggesting a fundamental role of hs1.2 enhancer variants in the Ig expression in children.
Results and discussion
Allelic frequencies of hs1.2 enhancer in children (A) and adults (B) divided for the serum levels of Ig
0.02 ± 0.01
0.48 ± 0.05
0.41 ± 0.04
0.05 ± 0.02
0.49 ± 0.04
0.40 ± 0.06
0.05 ± 0.03
0.43’ ± 0.04
0.46 ± 0.04
0.81 ± 0.04
0.44 ± 0.03
0.47 ± 0.06
0.79 ± 0.04
0.39 ± 0.05
0.49 ± 0.04
0.82 ± 0.03
0.1 ± 0.03
0.1 ± 0.02
0.17 ± 0.03
0.08 ± 0.02
0.12 ± 0.03
0.16 ± 0.03
0.12 ± 0.03
0.11 ± 0.03
0.13 ± 0.02
0.29 ± 0.03
0.32 ± 0.03
0.25 ± 0.02
0.30 ± 0.02
0.30 ± 0.02
0.26 ± 0.02
0.34 ± 0.03
0.26 ± 0.04
0.27 ± 002
0.56 ± 0.04
0.54 ± 0.02
0.58 ± 0.03
0.54 ± 0.04
0.55 ± 0.06
0.58 ± 0.04
0.52 ± 0.04
0.58 ± 0.03
0.57 ± 0.07
0.13 ± 0.02
0.13 0.13 0.03
Ig median follow-up from 5 to 8 years
5 years (mg/dl)
8 years (mg/dl)
5 years (mg/dl)
8 years (mg/dl)
5 years (mg/dl)
8 years (mg/dl)
1030 ± 0.09
Previous evidence showed the association of Ig levels with 3’RR1 enhancer hs1.2 polymorphism in autoimmune diseases. In these experiments we studied the role of hs1.2 polymorphism in physiological conditions in healthy subjects. Our results show that in children there is a significant correlation between different hs1.2 alleles and Ig expression levels, suggesting that hs1.2 polymorphism might primarily influence the concentration of Ig classes in serum during childhood. Moreover the follow-up of the children homozygous for the *1 allele showed that, after the fifth year of age, the Ig median values for all three classes increase; instead, in subjects homozygous for the *2 allele the values strongly decrease. This trend leads to the final adult equilibrium observed where no correlation is shown with Ig levels and hs1.2 alleles.
Our data imply that during physiological development there is a switch of regulatory mechanisms involved in Ig expression that might be reverted in autoimmune diseases -. The similar distribution of B cells subpopulations in homozygous children for *1 and *2 alleles (most frequent in European populations) suggests that the different Ig levels are obtained by different Ig secretion of the cells and not by the different number of B cells.
In conclusion we like assessing that there is a mechanism, correlated to hs1.2 polymorphism, that in children leads to a parallel control of IgA, IgG and IgM, while in adulthood changes to produce the three Ig classes at different concentrations.
These observations raise the possibility that in children the polymorphism of the hs1.2 enhancer is a relevant component in regulatory mechanism involved in Ig expression. The presence in Europe of higher *2 allele  and these results related to Ig levels in children can give an explanation for the selective advantage of the allele balanced by the disadvantage in adulthood for the association to autoimmune disease. It must be mentioned that in humans the presence of two copies of hs1.2 derived by the duplication of the 3’RR can give the possibility to the alleles of the first copy at 3’ of alpha-1 to influence the regulation otherwise absent if the gamma 2/4, epsilon and alpha-2 switch occurs.
Moreover this evidence answers the question about the function of the alleles. In fact, the positive association of *2 allele with high Ig levels in childhood could be the reason for the positive selection after the migration out of Africa: a condition of shorter life expectancy could have led to a reduced risk for immune-diseases development.
Nevertheless, further studies will be required to address the role of hs1.2 during aging.
The cohort of healthy children was composed of 190 subjects (88 females and 102 males; age range 3’5 years; median age 3.75 years). A second cohort of 340 adult subjects consisted of 218 females (64%) and 122 males (36%) and with an age range from 19 to 33’years (median age 24 years). Research was carried out in compliance with the Helsinki Declaration and the study was approved by the Ethics Committee of Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico in Milan, Italy. The parents of all of the participants gave their written informed consent. From each individual, genomic DNA was extracted from blood by standard methods and a selective PCR for 3’RR1 region containing the polymorphic hs1.2 alleles was performed by conditions previously described . The frequencies of four hs1.2 alleles detected in two cohorts were evaluated by standard chi-square tests. The median value of Ig concentration of each cohort was used to get an equal number of subjects with low and high Ig levels, the group with medium level contained the remaining subjects. The range of Ig levels of each sub-group resulted as the minimum and maximum value of the subjects in that sub-group as a consequence of the subdivision determined by the median of the entire cohort. The dosage of Ig is mg/dl. The subjects were then classified arbitrarily by IgM, IgG and IgA serum concentrations (Low [L], Medium [M], and High [H]) respect to the median value and by age, children (<5 y/o) and adults (>19 y/o), as shown in Table 1A-B. All the subjects had Ig values within the normal range concentrations. Finally, fifty μl of whole blood was labeled as well by 6-color TBNKTM kit reagent (BD Biosciences), according to manufacturer recommendations for quantification and follow up of CD19+ cells.
ES, principal investigator, genotyping; CD, selection of pediatric subject; NP, blood sample treatment; LP, cell sorting and immunoassay; VI, adult control genotyping; CG, substantial contributions to conception and design; AM, selection of control subject; RM, clinical analysis; PD, statistic analysis; MC, substantial contributions to conception and design; VG, involved in drafting experimental flowchart, writing the manuscript and revising it; AP, substantial contributions to conception and design; SE, senior investigator of the pediatric group; DF, substantial contributions to conception and design, in drafting experimental flowchart, writing the manuscript and revising it. All authors read and approved the final manuscript.
The study was partially possible thanks to Domenico Frezza’s personal resources, the Italian Ministry of Health, and the Italian Ministry of Research for laboratory space and salaries. We are grateful to Tonia Brown and Lynell Bates for the English revision.
The Informed consent of subjects for this study was obtained after approval of the ethical committee of the Pediatric clinic of polyclinic of Milan and Policlinico of Tor Vergata.
- Orton SM FJ, Bellanti JA: Clinical applications of laboratory diagnostic immunology. Immunology IV: Clinical Application in Health and Disease. Edited by: Bellanti JA. 2012, Bethesda MD, I Care PressGoogle Scholar
- Pinaud E, Marquet M, Fiancette R, Peron S, Vincent-Fabert C, Denizot Y, Cogne M: The IgH locus 3’ regulatory region: pulling the strings from behind. Adv Immunol. 2011, 110: 27-70. 10.1016/B978-0-12-387663-8.00002-8.PubMedView ArticleGoogle Scholar
- Giambra V, Volpi S, Emelyanov AV, Pflugh D, Bothwell AL, Norio P, Fan Y, Ju Z, Skoultchi AI, Hardy RR, Frezza D, Birshtein BK: Pax5 and linker histone H1 coordinate DNA methylation and histone modifications in the 3’ regulatory region of the immunoglobulin heavy chain locus. Mol Cell Biol. 2008, 28 (19): 6123-6133. 10.1128/MCB.00233-08.PubMedPubMed CentralView ArticleGoogle Scholar
- Birshtein BK: The role of CTCF binding sites in the 3’ immunoglobulin heavy chain regulatory region. Front Genet. 2012, 3: 251-10.3389/fgene.2012.00251.PubMedPubMed CentralView ArticleGoogle Scholar
- Rouaud P, Vincent-Fabert C, Saintamand A, Fiancette R, Marquet M, Robert I, Reina-San-Martin B, Pinaud E, Cogne M, Denizot Y: The IgH 3’ regulatory region controls somatic hypermutation in germinal center B cells. J Exp Med. 2013, 210 (8): 1501-1507. 10.1084/jem.20130072.PubMedPubMed CentralView ArticleGoogle Scholar
- Chen C, Birshtein BK: Virtually identical enhancers containing a segment of homology to murine 3’IgH-E (hs1,2) lie downstream of human Ig C alpha 1 and C alpha 2 genes. J Immunol. 1997, 159 (3): 1310-1318.PubMedGoogle Scholar
- Chauveau C, Cogne M: Palindromic structure of the IgH 3’locus control region. Nat Genet. 1996, 14 (1): 15-16. 10.1038/ng0996-15.PubMedView ArticleGoogle Scholar
- Saleque S, Singh M, Little RD, Giannini SL, Michaelson JS, Birshtein BK: Dyad symmetry within the mouse 3’ IgH regulatory region includes two virtually identical enhancers (C alpha3’E and hs3). J Immunol. 1997, 158 (10): 4780-4787.PubMedGoogle Scholar
- D'Addabbo P, Scascitelli M, Giambra V, Rocchi M, Frezza D: Position and sequence conservation in Amniota of polymorphic enhancer HS1.2 within the palindrome of IgH 3’Regulatory Region. BMC Evol Biol. 2011, 11: 71-10.1186/1471-2148-11-71.PubMedPubMed CentralView ArticleGoogle Scholar
- Mills FC, Harindranath N, Mitchell M, Max EE: Enhancer complexes located downstream of both human immunoglobulin Calpha genes. J Exp Med. 1997, 186 (6): 845-858. 10.1084/jem.186.6.845.PubMedPubMed CentralView ArticleGoogle Scholar
- Giambra V, Fruscalzo A, Giufre M, Martinez-Labarga C, Favaro M, Rocchi M, Frezza D: Evolution of human IgH3’EC duplicated structures: both enhancers HS1,2 are polymorphic with variation of transcription factor's consensus sites. Gene. 2005, 346: 105-114. 10.1016/j.gene.2004.10.009.PubMedView ArticleGoogle Scholar
- Frezza D, Tolusso B, Giambra V, Gremese E, Marchini M, Nowik M, Serone E, D'Addabbo P, Mattioli C, Canestri S, Petricca L, D’Antona G, Birshtein BK, Scorza R, Ferraccioli G: Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. Ann Rheum Dis. 2012, 71 (8): 1309-1315. 10.1136/ard.2010.147025.PubMedView ArticleGoogle Scholar
- Frezza D, Giambra V, Cianci R, Fruscalzo A, Giufre M, Cammarota G, Martinez-Labarga C, Rickards O, Scibilia G, Sferlazzas C, Bartolozzi F, Starnino S, Magazzu G, Gasbarrini GB, Pandolfi F: Increased frequency of the immunoglobulin enhancer HS1,2 allele 2 in coeliac disease. Scand J Gastroenterol. 2004, 39 (11): 1083-1087. 10.1080/00365520410007999.PubMedView ArticleGoogle Scholar
- Cianci R, Giambra V, Mattioli C, Esposito M, Cammarota G, Scibilia G, Magazzu G, Orlando A, Sandri G, Bianchi L, Gasbarrini GB, Pandolfi F, Frezza D: Increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis. J Invest Dermatol. 2008, 128 (8): 1920-1924. 10.1038/jid.2008.40.PubMedView ArticleGoogle Scholar
- Tolusso B, Frezza D, Mattioli C, Fedele AL, Bosello S, Faustini F, Peluso G, Giambra V, Pietrapertosa D, Morelli A, Gremese E, De Santis M, Ferraccioli GF: Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Ann Rheum Dis. 2009, 68 (3): 416-419. 10.1136/ard.2008.095414.PubMedPubMed CentralView ArticleGoogle Scholar
- Giambra V, Cianci R, Lolli S, Mattioli C, Tampella G, Cattalini M, Kilic SS, Pandolfi F, Plebani A, Frezza D: Allele *1 of HS1.2 enhancer associates with selective IgA deficiency and IgM concentration. J Immunol. 2009, 183 (12): 8280-8285. 10.4049/jimmunol.0902426.PubMedView ArticleGoogle Scholar
- Fernando TM, Ochs SD, Liu J, Chambers-Turner RC, Sulentic CE: 2,3,7,8-tetrachlorodibenzo-p-dioxin induces transcriptional activity of the human polymorphic hs1,2 enhancer of the 3’Igh regulatory region. J Immunol. 2012, 188 (7): 3294-3306. 10.4049/jimmunol.1101111.PubMedPubMed CentralView ArticleGoogle Scholar
- Giambra V, Martinez-Labarga C, Giufre M, Modiano D, Simpore J, Gisladottir BK, Francavilla R, Zhelezova G, Kilic SS, Crawford M, Biondi G, Rickards O, Frezza D: Immunoglobulin enhancer HS1,2 polymorphism: a new powerful anthropogenetic marker. Ann Hum Genet. 2006, 70 (Pt 6): 946-950. 10.1111/j.1469-1809.2006.00273.x.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.